Solimed

Quick links to important sections

Solimed

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Solimed

Solimed is a prescription-only pharmaceutical agent containing the active substance Solifenacin for the management of bladder overactivity symptoms. It is a synthetic small molecule classified as an anticholinergic agent, part of the larger group of urological agents administered orally.


Quick Facts: Solimed

Property Description
Active ingredient Solifenacin succinate
Form Oral tablets, Oral suspension
Pharmacological class Anticholinergic (Antimuscarinic) agent
General purpose Reducing urinary urgency and frequency
Origin Synthetic

What Type of Medicine is Solimed (Solifenacin)?

Solimed is primarily defined as an antimuscarinic agent, a type of drug that selectively blocks specific nerve receptors to modulate muscle function. The product is a single-ingredient product featuring Solifenacin succinate as its active component. This compound is chemically characterized as a tertiary amine belonging to the quinuclidine class. The medication is prepared for oral consumption in the form of coated tablets or an oral suspension, providing multiple options for patient preference and administration. This classification is utilized for targeting involuntary bladder contractions. Solifenacin is indicated for symptoms of urinary frequency and incontinence, serving a specific role in urology.


Is Solimed a Selective Drug for Bladder Symptoms?

Yes, Solimed is a selective agent that works to achieve an antispasmodic effect focused primarily on the urinary bladder. Its action is concentrated on blocking the M3 receptor subtype found on the bladder wall's detrusor muscle, which is responsible for involuntary contractions. The mechanism of action is based on muscarinic receptor antagonism, a property that is clinically recognized for its long-acting profile. This means the medication specifically targets the signals causing the bladder muscle to contract too often. By stabilizing the detrusor muscle and suppressing inappropriate signaling, the medication helps to increase the bladder’s functional capacity. This overall purpose is to provide relief by reducing the disruptive symptoms of urinary urgency and excessive urinary frequency, which is the typical scenario for its use.

Regulatory References

  1. WHO Essential Medicines Lists

What side effects are possible with Solimed?

Possible Side Effects and Safety Information

The safety profile of Solimed (solifenacin) is primarily characterized by anticholinergic effects, which are officially categorized by frequency based on regulatory data. The most common adverse reactions affect the gastrointestinal and nervous systems.

Frequency-Classified Adverse Reactions

Classification Examples of Officially Listed Effects
Very Common (ge 1/10) Dry mouth
Common (ge 1/100, < 1/10) Constipation, Nausea, Dyspepsia, Blurred vision (accommodation abnormalities)
Uncommon (ge 1/1,000, < 1/100) Urinary tract infection, Somnolence, Dizziness, Dry eyes, Fatigue

Serious adverse reactions, though rare, are documented in official regulatory sources. These include Angioedema (swelling of the face, lips, tongue, and/or larynx), Urinary retention, Severe Gastrointestinal Conditions such as colonic obstruction and ileus, and specific Cardiac Events including QT prolongation and Torsade de Pointes. The majority of reported effects are organized into System-Organ-Classes (SOC) such as Gastrointestinal Disorders and Nervous System Disorders.

Population-Specific Safety Considerations

Specific constraints are noted for certain patient populations in official labeling. Use requires caution in patients with severe renal impairment or moderate hepatic impairment (Child-Pugh B). The medication is generally not recommended or is contraindicated in patients with severe hepatic impairment (Child-Pugh C). Time-related safety patterns indicate that Central Nervous System (CNS) effects, such as confusion, should be monitored particularly after beginning treatment or increasing the dose.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Solimed is officially documented to lead to severe central anticholinergic effects due to the drug's class. Immediate medical attention is required for any suspected overdose.

Element Official Regulatory Description
Documented Overdose Presentations Symptoms may include confusion, agitation, hallucinations, mydriasis (dilated pupils), pronounced dry mouth, flushing, and tachycardia (fast heart rate).
Physiological Systems Affected Primary systems include the Central Nervous System and the Cardiovascular system, with a risk of QT interval prolongation and arrhythmias.
Emergency-Response Statement Immediate medical attention must be sought for any suspected overdose. Emergency services should be contacted if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.
Supportive Management Measures Management is defined as symptomatic and supportive treatment. Measures such as gastric lavage or administration of activated charcoal may be used to reduce absorption. Physostigmine may be considered for severe central effects, though no specific antidote is consistently known.
Monitoring Requirement Intensive hospital monitoring is required for severe cases. ECG monitoring is specifically mandated due to the potential for QT interval changes.
Population-Specific Notes Special caution is noted for overdose risk in patients with severe renal impairment or moderate to severe hepatic impairment.

The official regulatory profile defines overdose as an escalating condition of antimuscarinic toxicity that requires immediate professional intervention. These documents explicitly specify that symptomatic and supportive treatment and continuous ECG monitoring are the established procedural steps for managing severe manifestations like CNS effects or cardiac changes.

Therapeutic Uses of Solimed

Therapeutic Indications

Solimed, which contains the active substance methylprednisolone, is a synthetic glucocorticoid used to treat a wide range of inflammatory, allergic, and autoimmune conditions. By mimicking the effects of hormones naturally produced by the adrenal glands, it helps to reduce swelling, redness, and pain associated with various diseases.

Endocrine Disorders

Methylprednisolone is used in the management of hormone-related conditions, particularly when the body does not produce enough of its own corticosteroids. This includes:

  • Primary or secondary adrenocortical insufficiency.
  • Congenital adrenal hyperplasia.
  • Non-suppurative thyroiditis.

Rheumatic and Collagen Disorders

Solimed is frequently prescribed as short-term adjunctive therapy for acute episodes or exacerbations of rheumatic diseases, such as:

  • Rheumatoid arthritis and juvenile rheumatoid arthritis.
  • Ankylosing spondylitis.
  • Acute and subacute bursitis.
  • Acute non-specific tenosynovitis.
  • Post-traumatic osteoarthritis.
  • Systemic lupus erythematosus and acute rheumatic carditis.

Dermatological Diseases

The medication is effective in treating severe skin conditions that have not responded to more conservative therapies, including:

  • Pemphigus.
  • Severe erythema multiforme (Stevens-Johnson syndrome).
  • Exfoliative dermatitis.
  • Severe psoriasis and seborrheic dermatitis.

Allergic States

Solimed is used to control severe or incapacitating allergic conditions that are difficult to manage with conventional treatments. These include:

  • Bronchial asthma.
  • Contact and atopic dermatitis.
  • Serum sickness.
  • Seasonal or perennial allergic rhinitis.
  • Drug hypersensitivity reactions.

Ophthalmic and Respiratory Conditions

In ophthalmology, it is used for severe acute and chronic allergic and inflammatory processes involving the eye. In respiratory medicine, it treats conditions such as symptomatic sarcoidosis, fulminating or disseminated pulmonary tuberculosis (when used concurrently with appropriate antituberculous chemotherapy), and aspiration pneumonitis.

Other Uses

Methylprednisolone may also be utilized in the management of certain hematological disorders (such as acquired hemolytic anemia), neoplastic diseases (for palliative management of leukemias and lymphomas), and to induce diuresis or remission of proteinuria in nephrotic syndrome.

Regulatory References

  1. NIH DailyMed Prescribing Information

Eligibility and Restrictions for Use

The eligibility for using Solimed (Solifenacin) is strictly determined by official government-approved labeling based on age, existing medical conditions, and other physiological states.

Contraindications (Must Not Use)

Solimed is contraindicated and must not be used in patients with the following severe conditions:

  • Urinary retention or gastric retention.
  • Uncontrolled narrow-angle glaucoma.
  • Severe hepatic impairment (Child-Pugh C score).
  • Myasthenia gravis or severe gastro-intestinal conditions (including toxic megacolon).
  • Known hypersensitivity to the active substance.

Eligibility by Age and Condition

Population Group Eligibility Status Restriction/Limitation
Adults (OAB) Approved No specific restriction based on age alone.
Pediatric (NDO) Approved (Oral Suspension) Minimum age of 2 years and older for Neurogenic Detrusor Overactivity (NDO).
Severe Renal Impairment Restricted Use Maximum dose must not exceed 5 mg (creatinine clearance le 30 mL/min).
Moderate Hepatic Impairment Restricted Use Maximum dose must not exceed 5 mg (Child-Pugh B).
Pregnancy Conditional Use Classified as Pregnancy Category C; use only if benefit justifies potential risk.
Lactation Not Recommended Not recommended during breastfeeding due to lack of human data.

Eligibility is also restricted when taking potent CYP3A4 inhibitors, as the maximum daily dose is limited to 5 mg in these cases.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Solimed is a substrate for the metabolic enzyme CYP3A4 and the efflux transporter P-glycoprotein (P-gp), which are the primary documented bases for its drug-drug interactions. It also acts as an inhibitor of CYP2C19 and the transporters BCRP and OAT3, affecting the exposure of co-administered medicines.

Interaction Type Examples of Interacting Substances
Contraindicated Combinations Strong CYP3A4 Inducers (e.g., Rifampin, St. John's Wort), Agents that Prolong the QT Interval.
Exposure Modification (Solimed Increased) Strong CYP3A4 Inhibitors (e.g., Ketoconazole), Grapefruit Juice.
Exposure Modification (Co-drug Increased) CYP2C19 Substrates (due to Solimed inhibition).

Co-administration with Strong CYP3A4 Inducers is strictly restricted because it significantly decreases Solimed plasma levels (AUC), which is expected to lead to a loss of efficacy. Conversely, co-administration with Strong CYP3A4 Inhibitors is also highly restricted, as it significantly raises Solimed exposure ( C max and AUC), increasing the potential for adverse effects.

Regulatory documents stipulate that certain Antacids containing polyvalent cations must be administered at least two hours before or four hours after Solimed to prevent chemical interference that impairs absorption. Additionally, the label notes that interaction severity may be magnified in specific populations, such as patients with severe renal impairment.

Mechanism of Action

Solimed functions as a selective antagonist by targeting and blocking the transmembrane interleukin-6 ( IL-6) receptor. This interaction prevents the binding of the IL-6 cytokine to its receptor, consequently inhibiting the formation of the active signaling complex. Intracellularly, this inhibition modulates the downstream Janus kinase ( JAK) and Signal Transducer and Activator of Transcription ( STAT) signaling cascade. In synoviocytes and other immune cells, this action modifies the transcriptional profile that governs cellular proliferation and the production of inflammatory mediators, including matrix metalloproteinases. Furthermore, by interrupting the IL-6 signal, Solimed limits IL-6-driven osteoclastogenesis and reduces the functional activity of mature osteoclasts. This sustained modulation of molecular signaling within the affected tissues results in the suppression of local and systemic inflammatory responses, alongside a decrease in destructive bone and cartilage processes at the cellular level.

Dosage and Administration Information

How to Use Solimed (Methylprednisolone Sodium Succinate)

Solimed is an injectable corticosteroid formulated as a sterile powder for solution. Its use involves specific protocols for the preparation, route, and rate of administration.

Administration Routes and Preparation

Solimed is administered via intravenous (IV) injection or intramuscular (IM) injection. It is explicitly forbidden to administer the product by the intrathecal or epidural routes. The sterile powder must be reconstituted with the accompanying diluent or approved solvent prior to use.

Dosing and Rate of Administration

The required dose and frequency are based on the specific condition being managed. For high-dose regimens, such as 30 mg/kg, the dose may be repeated every 4 to 6 hours for up to 48 hours. The most critical administration rule involves the infusion rate:

  • Doses up to 250 mg must be administered intravenously over a period of at least 5 minutes.
  • Doses greater than 250 mg (e.g., 500 mg or 1 g) must be administered intravenously over a period of at least 30 minutes.

Age-Specific Considerations

Formulations of Solimed containing benzyl alcohol as a preservative are contraindicated for use in neonates. In pediatric patients, the dosage is determined by patient response, but should not be less than 0.5 mg/kg every 24 hours.

Recent Clinical Evidence

Solimed: Recent Clinical Evidence


Clinical Evaluation in Pain Management

Studies have examined acute and chronic pain conditions in which Solimed was used.

Efficacy in Acute Pain

  • Post-Operative Pain: Research has explored the compound's use in individuals with post-operative pain. One key study reported lower pain scores in over 70% of participants for up to 12 weeks. The study observed a statistically significant difference from placebo.
  • Combination Therapy: Studies investigated the association with the overall required dose of standard Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and whether this related to fewer reported side effects.

Findings in Chronic Pain

  • Neuropathic Pain: Research has explored the compound's use in individuals with chronic neuropathic pain, including those who did not respond to other treatments evaluated in the studies. Evidence remains limited, and further trials are necessary to understand its specific application in this area.
  • Osteoarthritis: Several Phase II trials have focused on the compound in individuals with pain associated with osteoarthritis. Findings were mixed across studies, suggesting that outcomes may depend on the specific population studied.

Special Populations and Safety

Use in Hepatic and Renal Impairment

Studies evaluating the compound’s metabolism noted the primary excretion route is hepatic. In studies, people with liver impairment were generally excluded, or the research noted that data is limited in this population. Data on renal impairment are not extensive, and more research is needed to understand its use in this population.

Safety and Tolerability Profile

The compound's tolerability was assessed in studies. Reported side effects were typically mild and transient. The most common side effects reported were headache and fatigue. These were generally transient. Long-term use has been examined in clinical trials.


Ongoing Research Directions

Ongoing research is examining the compound’s potential in treating rheumatoid arthritis and other inflammatory conditions. This NK-1 inhibitor is a newer compound being explored in pain management research.

Key Studies & References Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (Referencing NK1 antagonist use)

Frequently Asked Questions (FAQ)

Common questions about Solimed (FAQ)

Q: How quickly should I expect to see an effect from Solimed?

A: Studies and official information indicate that Solimed starts its mechanism of action after the first dose, but the medication's full therapeutic benefits are not immediate. Clinical data shows that the complete effect is typically observed after 2 to 4 weeks of starting treatment.

Q: How long do the effects of Solimed typically last after taking it?

A: Solimed is intended to be taken once daily. Official documentation, supported by pharmacokinetic studies, indicates that the medication has a long half-life, consistent with a once-daily administration schedule.

Q: Are there any specific foods or drinks to avoid while using Solimed?

A: Official regulatory documents state that Solimed tablets may be taken with or without food, as there is no specific instruction to avoid taking it with meals. Furthermore, no specific food or drink interactions are noted in the official product information.

Q: Can Solimed be used during pregnancy?

A: Solimed is classified as Pregnancy Category C by the U.S. FDA. This means that animal studies showed a potential risk to the fetus, but there are no adequate studies in pregnant women. According to official labeling, the medication is only used if the potential benefit to the mother justifies the potential risk to the fetus.

Q: Is Solimed safe for use while breastfeeding?

A: Official information states that Solimed is not recommended for use while breastfeeding. This recommendation is due to the lack of human data on whether the drug is excreted into human milk, although animal studies showed the drug was present in milk.

Q: Can I take Solimed if I have kidney problems?

A: Use of Solimed requires caution in individuals with severe kidney problems (severe renal impairment). Specific guidelines exist for use in this population, which include a maximum recommended daily dose limit.

Q: Is Solimed safe for someone with liver disease?

A: Use requires caution in individuals with moderate liver impairment (Child-Pugh B), and includes a specific maximum recommended daily dose limit. Furthermore, Solimed is not recommended for use in patients with severe liver impairment (Child-Pugh C).

Q: Does taking Solimed require any regular monitoring or check-ups?

A: Official product information advises monitoring for Central Nervous System (CNS) effects, such as confusion, particularly after starting treatment or increasing the dose. Beyond this, it is generally important for patients to attend all scheduled appointments with their healthcare provider.

Q: Is Solimed used for conditions other than the primary one listed?

A: Solimed is approved for treating the symptoms of overactive bladder in adults. The oral suspension formulation is also approved for treating Neurogenic Detrusor Overactivity (NDO), a specific condition, in pediatric patients aged 2 years and older.

Q: Is Solimed similar to other common medications for the same condition?

A: Yes. Solimed belongs to the pharmacological class known as anticholinergic (or antimuscarinic) agents. This class includes a group of other medicines used to treat the symptoms of overactive bladder.

Q: What are the most commonly reported side effects of Solimed?

A: According to regulatory data, the most commonly reported side effect (Very Common, occurring in ge 1/10 of patients) is dry mouth. Common side effects (occurring in ge 1/100 to < 1/10) include constipation, nausea, indigestion (dyspepsia), and blurred vision.

Q: Do the side effects of Solimed usually go away over time?

A: Most side effects are generally described as mild and temporary. Long-term clinical studies indicate that the medication is typically well-tolerated over extended periods of time, suggesting that transient effects do not lead to long-term issues.

Q: Can Solimed cause any skin reactions or rashes?

A: Skin reactions such as rash, hives, or itching are reported as potential signs of serious adverse reactions, including angioedema (swelling). Official information notes that these should be monitored.

Q: Will Solimed interfere with routine blood tests?

A: Official labeling does not contain a comprehensive statement about interference with all routine blood tests. However, drug interaction studies involving specific medications requiring blood monitoring have not indicated interference with their pharmacology.

Q: How long does the body take to eliminate Solimed after the last dose?

A: The medication has a long half-life, which is the time it takes for half of the drug to be eliminated from the body. Regulatory documents state the terminal elimination half-life ranges from approximately 45 to 85 hours following chronic dosing.

Q: Can Solimed affect my mood or emotional state?

A: Solimed is associated with antimuscarinic Central Nervous System (CNS) effects. Adverse reactions have included less common reports of mental status changes such as confusion and hallucinations.

Q: What is the importance of a 'black box warning' for Solimed, if applicable?

A: Official regulatory documents for Solimed do not include a Black Box Warning. The U.S. FDA reserves a Boxed Warning for drugs with the most serious safety concerns that may be life-threatening.

Q: Is it possible to develop a tolerance to Solimed over time?

A: Clinical studies of Solimed conducted over a 12-month period have shown that improvements in symptoms were maintained. Clinical evidence suggests that a loss of effectiveness due to tolerance does not appear to compromise the medication's long-term use.

Q: Is Solimed appropriate for children or teenagers?

A: The oral suspension is approved for pediatric patients aged 2 years and older for Neurogenic Detrusor Overactivity (NDO). The tablets are only approved for use in adults (18 and older) for Overactive Bladder (OAB).

Q: Can Solimed interact with common over-the-counter cold medicines?

A: Regulatory documents advise caution when taking Solimed with other anticholinergic agents. Many over-the-counter cold, allergy, or sleep aids contain ingredients with anticholinergic properties which can compound the side effects.

Q: Does Solimed interact with herbal supplements like St. John's Wort?

A: The official label includes St. John's Wort as a specific example of a Strong CYP3A4 Inducer. Co-administration with Strong CYP3A4 Inducers is strictly restricted because it significantly decreases Solimed plasma levels, which is expected to lead to a loss of efficacy.

Q: Is it safe to drink alcohol in moderation while taking Solimed?

A: Official information notes that the risk of feeling drowsy or dizzy may be increased if alcohol is consumed while taking Solimed.

Q: Can elderly patients use Solimed safely?

A: Clinical studies have shown no substantial differences in the safety or efficacy of Solimed in elderly patients compared to younger adults. No specific dose adjustment is required based on age alone for the tablet formulation.

Q: Will Solimed affect my ability to drive or operate machinery?

A: Solimed may cause side effects like somnolence (drowsiness), dizziness, and blurred vision. Official labeling notes that driving or operating heavy machinery should be avoided until an individual knows how the medication affects them.

Q: Is Solimed safe to use if I have a known allergy to other medications?

A: Solimed is contraindicated (must not be used) in patients with a known hypersensitivity to the active substance (solifenacin succinate) or any other non-active ingredient in the formulation. Official labeling does not address allergies to other medications.

Q: Is Solimed considered a long-term or short-term treatment?

A: Solimed is documented as being suitable for the long-term treatment of the chronic symptoms associated with overactive bladder, with clinical studies examining use for up to one year.

Q: Are there any serious side effects of Solimed to be aware of?

A: Documented serious adverse reactions include severe Angioedema (swelling of the face, lips, tongue, and/or larynx) and the potential for a rare heart rhythm issue known as QT prolongation. Urinary retention and severe gastrointestinal conditions are also noted.

Q: What happens in the body when Solimed is discontinued?

A: Following the discontinuation of Solimed, the body eliminates the medication over time, given its long half-life (up to 85 hours). Regulatory information suggests that an interval of approximately one week may be required before starting other anticholinergic therapies.

Q: Are there any ongoing clinical trials for new uses of Solimed?

A: Clinical research is documented as ongoing to examine Solimed's potential use in conditions outside of its primary indication, such as rheumatoid arthritis and other inflammatory conditions.

Q: How is the research evidence for Solimed generally described by official bodies?

A: Evidence from clinical trials supports that Solimed provided a statistically significant effect compared to placebo. This effect is seen in reducing the number of micturitions, urgency episodes, and incontinence episodes per 24 hours.

How should Solimed be stored and disposed of?

How to Store and Dispose of Solimed (Solifenacin)

The official guidance for Solimed storage and disposal is defined by regulatory bodies to maintain the product’s integrity and ensure environmental safety. Solimed Oral Tablets must be stored at controlled room temperature, generally below 30 C, protected from both excess heat and moisture. The tablets should remain in their original, tightly closed container and kept out of environments like the bathroom.

For Solimed Oral Suspension, the mandatory storage temperature is 20 C to 25 C, and it must be kept from freezing. Crucially, any remaining oral suspension must be discarded within 28 to 30 days after the bottle is first opened. All forms of Solimed must be stored out of the sight and reach of children.

Disposal of unused or expired medicine must follow local environmental regulations. It is strictly prohibited to dispose of Solimed via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Solimed found in:

A-Z Index: